An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer

Rafael Grochot, Christina Guo, Suzanne Carreira, Mateus Crespo, Jon Welti, Susana Miranda, Ines Figueiredo, Claudia Bertan, Jan Rekowski, Wei Yuan, Nina Tunariu, Katarzyna Abramowicz, Ana Ferreira, Ruth Riisnaes, Antje Neeb, Bora Gurel, Maria de Los Dolores Fenor de la Maza, Khobe Chandran, Juliet Carmichael, Daniel Westaby, Hella Kohlhof, Adam Sharp, Alec Paschalis, Johann de Bono

European Urology Oncology
Published: March 11, 2026

https://doi.org/10.1016/j.euo.2026.02.014